AB Science announced the recruitment of the first patient in its Phase 3 study evaluating masitinib for severe persistent asthma.
Your search for oral corticosteroids returned 9 results
Novartis announced data from its Phase 3 study of ACZ885 (canakinumab) for the treatment of children with active systemic juvenile idiopathic arthritis (SJIA).
The submission was based on data from the double-blind, placebo-controlled VOYAGE trial.
The BLA submission is supported by data from the PATHFINDER clinical program.
Acton announced that it has submitted a supplemental New Drug Application (sNDA) to the FDA for its new asthma product, Aerospan (flunisolide HFA, 80 mcg) Inhalation Aerosol.
Lux Biosciences reported the results from three Phase 3 LUMINATE trials of the company’s LX211 (Luveniq, voclosporin capsules) drug candidate for the treatment of uveitis.
Santarus announced pooled data from two Phase 3 studies of Uceris (budesonide MMX) for the induction of remission of mild or moderate active ulcerative colitis.
Rilzabrutinib is an oral Bruton tyrosine kinase inhibitor currently in development for a number of immune-mediated diseases.
Vamorolone is a first-in-class dissociative steroidal drug that retains the anti-inflammatory activity of corticosteroids but with a novel mechanism of action.